Literature DB >> 2252125

Glucagonoma syndrome is an underdiagnosed clinical entity.

J A Edney1, S Hofmann, J S Thompson, A Kessinger.   

Abstract

Glucagonomas, considered among the rarest of the islet cell neoplasms, produce a well-defined clinical syndrome characterized by necrolytic migratory erythema, diabetes mellitus, glossitis, anemia, and weight loss. This report describes seven patients with glucagonoma treated at our institution. All seven had the characteristic dermatologic manifestations, present from 1 to 6 years prior to diagnosis. Five patients had extensive disease at the time of initial operation, three of whom underwent aggressive cytoreductive surgery, whereas the other two had biopsy only. The remaining two patients presented with a single nodule each, underwent distal pancreatectomy and splenectomy, and remain free of disease 2 and 6 years postoperatively. Earlier recognition of the distinctive physical findings peculiar to this syndrome should increase survival. Aggressive cytoreductive surgery results in prolonged remission.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2252125     DOI: 10.1016/s0002-9610(05)80761-5

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Endoscopic findings of a pancreatic glucagonoma.

Authors:  A G Guirado; P Sanchez-Fayos; O Bosch; M J Relloso; C Rivas; J C Porres
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

2.  Is glucagonoma of the pancreas a curable disease?

Authors:  Q D Chu; M F Al-kasspooles; J L Smith; H R Nava; H O Douglass; D Driscoll; J F Gibbs
Journal:  Int J Pancreatol       Date:  2001

3.  Cystic glucagonoma: A rare variant of an uncommon neuroendocrine pancreas tumor.

Authors:  K Brown; T Kristopaitis; S Yong; G Chejfec; J Pickleman
Journal:  J Gastrointest Surg       Date:  1998 Nov-Dec       Impact factor: 3.267

4.  Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor.

Authors:  Sheng-li Wu; Ji-gang Bai; Jun Xu; Qing-yong Ma; Zheng Wu
Journal:  World J Surg Oncol       Date:  2014-07-17       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.